ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Impact of Preoperative Mod/Sev MR on 2-Year Outcome After TAVI and AVR Insight From the PARTNER Trial

Thursday, January 2, 2014

Submitted by

Source

Source Name: Circulation

Source URL: http://www.ncbi.nlm.nih.gov/pubmed/24152861

Author(s)

Barbanti M, Webb JG, Hahn RT, Feldman T, Boone RH, Smith CR, Kodali S, Zajarias A, Thompson CR, Green P, Babaliaros V, Makkar RR, Szeto WY, Douglas PS, McAndrew T, Hueter I, Miller DC, Leon MB; Placement of Aortic Transcatheter Valve (PARTNER) Trial Investigators

In this paper the authors use data from cohort A of the PARTNER trial to evaluate the effect of preoperative moderate to severe mitral regurgitation on survival at two years in patients treated with surgical aortic valve replacement (SAVR) and TAVI. Mitral regurgitation improved significantly in both groups at 30 days. Preoperative mitral regurgitation had a negative effect on survival in the SAVR group but not in the TAVI group. The authors conclude that TAVI may be a reasonable treatment option in a selected group of patients with aortic stenosis and mitral regurgitation.